Rhythm Pharmaceuticals (RYTM) Earnings Date & Reports

Key Takeaways

• Rhythm Pharmaceuticals (RYTM) is scheduled to report second-quarter 2026 earnings on Tuesday, August 4, 2026, before the market opens.
• Consensus estimates project a net loss of approximately $0.81 per share on revenue of roughly $67.5 million, representing strong year-over-year top-line growth from $48.5 million in Q2 2025.
• The recent U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO) will be a central focus, with investors tracking early prescription trends and payer policy developments.
• International revenue momentum is accelerating, driven by expanded access in Germany, France, and named-patient markets across Europe and the Middle East.
• Analyst sentiment remains overwhelmingly positive, with a consensus Strong Buy rating and an average 12-month price target near $140, implying potential upside of more than 35% from recent trading levels.
• Pipeline updates — including data on bivamelagon (RM-718) and Prader-Willi syndrome (PWS) — could shape the long-term investment narrative beyond the quarterly numbers.

Earnings Context and Why It Matters

Rhythm Pharmaceuticals has reached a critical inflection point. The company, which specializes in precision therapies targeting the melanocortin-4 receptor (MC4R) pathway for rare genetic obesity disorders, secured U.S. Food and Drug Administration (FDA) approval for IMCIVREE (setmelanotide) in acquired hypothalamic obesity in March 2026. This greatly expanded its addressable patient population. With first-quarter 2026 revenue surging nearly 84% year-over-year to $60.1 million and the commercial infrastructure now scaled to 42 U.S. sales representatives, the Q2 report will serve as the first full-quarter read on the HO launch trajectory. For investors, this earnings release is not just about beating or missing consensus — it is about validating whether the company's commercial expansion strategy is translating into sustained, scalable revenue growth.

Earnings Expectations

Wall Street analysts expect Rhythm Pharmaceuticals to report a net loss of approximately $0.81 per share for the second quarter of 2026, according to consensus data compiled by MarketWatch and TipRanks. Revenue is projected to reach roughly $67.5 million, which would mark a nearly 40% increase from the $48.5 million reported in the same quarter a year ago and a roughly 12% sequential gain from Q1 2026.

The year-ago comparison highlights meaningful operating expense growth. In Q2 2025, Rhythm posted a net loss of $0.75 per share on $48.5 million in revenue. Since then, selling, general and administrative (SG&A) expenses have climbed sharply — reaching $63.6 million in Q1 2026 compared with $39.1 million a year earlier — reflecting the salesforce expansion and commercial investments tied to the HO launch. The company has guided full-year 2026 non-GAAP (Generally Accepted Accounting Principles) operating expenses to a range of $385 million to $415 million, and investors will closely monitor whether expense growth is tracking in line with that outlook.

Historically, Rhythm has delivered mixed results relative to consensus. The company beat EPS estimates in two of its last four quarters but missed in the other two. Q1 2026 came in $0.03 ahead of expectations, while Q3 and Q2 of 2025 both missed by wider margins. Revenue has been a brighter spot, with the company exceeding top-line consensus in seven of the past eight quarters.

Key metrics beyond the headline numbers include the number of patients on reimbursed IMCIVREE therapy (which grew 8% sequentially in Q1), the pace of new HO start forms and prescription conversions, gross-to-net pricing dynamics in the U.S., and international revenue contribution — which jumped 27% quarter-over-quarter in Q1 to $23.2 million.

AI Screener

Investors preparing for earnings season can streamline their research with Tickeron's AI Screener, an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market with precision. The screener scans thousands of stocks and ETFs using customizable criteria including industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-driven signals. Whether monitoring biotechnology names like Rhythm Pharmaceuticals ahead of earnings or scanning for breakout candidates across any sector, the AI Screener helps surface trade ideas and trending opportunities far more efficiently than manual screening. Explore the full functionality to identify high-potential setups before the market reacts.

Market Reaction and Investor Sentiment

Heading into the Q2 print, market sentiment around Rhythm Pharmaceuticals is broadly constructive but not without tension. The stock has rallied significantly from its 52-week low of $74.50, and with a beta of approximately 1.88, it tends to amplify broader biotechnology sector movements. Analysts remain firmly in the bullish camp: of 17 covering firms, 14 rate the stock a Buy, two maintain a Hold, and one carries a Sell rating, producing a consensus Moderate Buy to Strong Buy depending on the data provider.

However, short interest is elevated at roughly 14.6% of the public float, signaling that a meaningful segment of the market remains skeptical. A sharper-than-expected quarterly loss, disappointing HO launch metrics, or higher-than-guided operating expense growth could provide ammunition for the bear case. Conversely, a revenue beat paired with encouraging launch commentary could trigger a short squeeze, given the size of the short position. The conference call, scheduled for 8:00 AM ET on August 4, will be closely parsed for management's tone on the HO commercial ramp, European market access timelines, and pipeline milestone updates.

Forward Outlook and Key Factors to Monitor

Beyond the second-quarter numbers, Rhythm Pharmaceuticals is entering a period dense with catalysts that could meaningfully influence the stock's trajectory through year-end 2026 and into 2027.

The most immediate focus is the HO commercial rollout. With more than 150 start forms received in the first six weeks post-approval and approximately 110 unique prescribers — roughly 80% of whom are new to IMCIVREE — early demand signals are encouraging. However, management has cautioned that HO-specific payer policies typically take three to nine months to mature, meaning the revenue contribution from this indication may build gradually rather than spike immediately.

On the regulatory front, Rhythm's New Drug Application (NDA) for setmelanotide in HO has been accepted by Japan's Pharmaceuticals and Medical Devices Agency (PMDA), with potential approval and launch anticipated by the end of 2026. In Europe, following the European Commission's marketing authorization, country-by-country launch preparations are underway, with initial EU commercial entries targeted for 2027. The pace of these geographic expansions will be critical for sustaining double-digit revenue growth.

Investors should also monitor the pipeline. The company expects to share Part C HO clinical data on the Q2 earnings call and has guided toward initiating a Phase 3 trial of bivamelagon (RM-718), a next-generation MC4R agonist, in HO before the end of 2026. Additionally, six-month Phase 2 data in Prader-Willi syndrome, presented at ENDO 2026, could open yet another large rare-disease opportunity. Each of these readouts carries the potential to reshape the long-term revenue outlook.

Finally, cash runway remains a key gauge of financial flexibility. Rhythm ended Q1 with approximately $341 million in cash, cash equivalents, and short-term investments, which management has stated is sufficient to fund operations for at least 24 months. With non-GAAP operating expenses expected to trend higher through the remainder of 2026 — driven by chemistry, manufacturing and controls (CMC) investments and clinical supply costs — any deviation from expense guidance would draw scrutiny.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations